177 related articles for article (PubMed ID: 17618427)
1. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 Sep; 63(9):829-36. PubMed ID: 17618427
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.
Karjalainen MJ; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2008 May; 64(5):511-9. PubMed ID: 18197403
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):157-65. PubMed ID: 18816299
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Granfors MT; Backman JT; Neuvonen M; Ahonen J; Neuvonen PJ
Clin Pharmacol Ther; 2004 Apr; 75(4):331-41. PubMed ID: 15060511
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
6. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
Backman JT; Granfors MT; Neuvonen PJ
Eur J Clin Pharmacol; 2006 Jun; 62(6):451-61. PubMed ID: 16758262
[TBL] [Abstract][Full Text] [Related]
7. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
Backman JT; Karjalainen MJ; Neuvonen M; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2006 Sep; 62(3):345-57. PubMed ID: 16934051
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2005 Oct; 78(4):400-11. PubMed ID: 16198659
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tizanidine as a marker of canine CYP1A2 activity.
Locuson CW; Williams P; Adcock JM; Daniels JS
J Vet Pharmacol Ther; 2016 Apr; 39(2):122-30. PubMed ID: 26228837
[TBL] [Abstract][Full Text] [Related]
10. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2004 Mar; 57(3):349-53. PubMed ID: 14998432
[TBL] [Abstract][Full Text] [Related]
11. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
[TBL] [Abstract][Full Text] [Related]
12. Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates.
Wang X; Lee WY; Or PM; Yeung JH
Phytomedicine; 2009 Aug; 16(8):712-25. PubMed ID: 19403289
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.
Kobayashi K; Nakajima M; Chiba K; Yamamoto T; Tani M; Ishizaki T; Kuroiwa Y
Br J Clin Pharmacol; 1998 Apr; 45(4):361-8. PubMed ID: 9578183
[TBL] [Abstract][Full Text] [Related]
14. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of tolfenamic acid in dogs. Evaluation of dose response relationships.
McKellar QA; Lees P; Gettinby G
Eur J Pharmacol; 1994 Mar; 253(3):191-200. PubMed ID: 8200415
[TBL] [Abstract][Full Text] [Related]
16. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.
Lilja JJ; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2007 Jun; 81(6):833-9. PubMed ID: 17392729
[TBL] [Abstract][Full Text] [Related]
17. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
Backman JT; Schröder MT; Neuvonen PJ
Eur J Clin Pharmacol; 2008 Jan; 64(1):17-24. PubMed ID: 17955229
[TBL] [Abstract][Full Text] [Related]
18. Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats.
Wang X; Yeung JH
J Pharm Pharmacol; 2010 Aug; 62(8):1077-83. PubMed ID: 20663043
[TBL] [Abstract][Full Text] [Related]
19. Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
Wattanachai N; Tassaneeyakul W; Rowland A; Elliot DJ; Bowalgaha K; Knights KM; Miners JO
Drug Metab Dispos; 2012 May; 40(5):982-9. PubMed ID: 22331994
[TBL] [Abstract][Full Text] [Related]
20. Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
Momo K; Homma M; Osaka Y; Inomata S; Tanaka M; Kohda Y
J Clin Pharmacol; 2010 Mar; 50(3):331-7. PubMed ID: 19789372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
